CasInvent Pharma

Executive Summary

CasInvent Pharma is a Czech Republic-based biotechnology company spun out from Masaryk University in 2020. The company is pioneering highly potent and selective small molecule inhibitors of Casein Kinase 1 (CK1) enzymes, aiming to overcome resistance in difficult-to-treat cancers such as Acute Myeloid Leukemia (AML) and solid tumors. By targeting CK1, a key regulator of cellular signaling pathways involved in cancer proliferation and drug resistance, CasInvent's approach has the potential to address significant unmet medical needs where existing targeted therapies fail.

Upcoming Catalysts (preview)

• Q1 2027Announcement of lead candidate selection and initiation of IND-enabling studies60% success
• Q2 2026Presentation of preclinical in vivo efficacy data at a major oncology conference70% success
• H2 2026Partnership or licensing deal with a larger pharmaceutical company30% success